CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) analog. Its primary function is to stimulate the pituitary gland to increase the secretion of growth hormone (GH), which indirectly raises insulin-like growth factor-1 (IGF-1) levels in the body.
1. Binding to Growth Hormone Receptors
CJC-1295 mimics the natural GHRH by binding to specific receptors on the pituitary gland, triggering the release of stored growth hormone into the bloodstream.
2. Enhanced Half-Life with DAC
The addition of DAC increases the peptide's half-life significantly compared to traditional GHRH.
The DAC complex binds to albumin (a protein in the blood), which protects the peptide from rapid degradation and provides a steady release over several days.
3. Pulsatile Growth Hormone Release
CJC-1295 with DAC promotes pulsatile (episodic) GH release rather than continuous secretion, which mimics the body's natural growth hormone rhythm.
This pattern helps prevent receptor desensitization and maximizes the benefits of growth hormone release.
4. Increased IGF-1 Production
Higher GH levels stimulate the liver to produce IGF-1, a hormone critical for growth, repair, and metabolic functions. IGF-1 is responsible for many of the anabolic effects attributed to growth hormone.
5. Long-Lasting Effects
Due to its extended half-life (up to 8-10 days), CJC-1295 with DAC requires less frequent administration (e.g., weekly or biweekly).
